SolarWinds (SWI) IPO Opens Modestly Higher

Today's IPO for SolarWinds (NYSE: SWI) opened for trading at $15.30 after pricing 25 million shares at $15.

In addition, SolarWinds has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Credit Suisse Securities (USA) LLC are acting as joint lead book-running managers for the offering. BofA Merrill Lynch, Barclays Capital Inc., Citigroup Global Markets Inc., Evercore Group L.L.C., Jefferies LLC, Macquarie Capital (USA) Inc., Nomura Securities International, Inc. and RBC Capital Markets, LLC are acting as joint book-running managers. JMP Securities LLC, KeyBanc Capital Markets Inc., Mischler Financial Group, Inc., Robert W. Baird & Co. Incorporated, Samuel A. Ramirez & Company, Inc. and SunTrust Robinson Humphrey, Inc. are acting as co-managers.

SolarWinds is a leading provider of powerful and affordable IT infrastructure management software. Our products give organizations worldwide, regardless of type, size or IT infrastructure complexity, the power to monitor and manage the performance of their IT environments, whether on-premise, in the cloud, or in hybrid models. We continuously engage with all types of technology professionals—IT operations professionals, DevOps professionals, and managed service providers (MSPs)—to understand the challenges they face maintaining high-performing and highly available IT infrastructures. The insights we gain from engaging with them, in places like our THWACK online community, allow us to build products that solve well-understood IT management challenges in ways that technology professionals want them solved. This focus on the user and commitment to excellence in end-to-end hybrid IT performance management has established SolarWinds as a worldwide leader in network management software and MSP solutions.

You May Also Be Interested In

• Kardigan shares soar after Nasdaq debut
• Pattern Group prices secondary offering of 8 million shares at $19 each
• ENLIVEN Therapeutics closes $460M public stock offering